Clinical Trials Group

Presentations and Publications

Recent Presentations

• September 2005 "Evaluation of Participation in TransATAC, a Companion International Research Study to ATAC" Poster presented at the 9th Nottingham International Breast Cancer Conference by Jill Knox, Norman Williams, Mitch Dowsett & Joan Houghton.
• December 2004 "Results of the ATAC Treatment Completion Analysis" presented at the 27th Annual San Antonio Breast Cancer Symposium by Professor Tony Howell, Chair of the ATAC Steering Committee, on behalf of the ATAC Trialists' Group.
• September 2004 "Delays in Correspondence with Local Research Ethics Committees" Poster presented at the British Oncological Association Scientific Meeting by Norman Williams, Kathryn McRae, and Joan Houghton.
• September 2003 "The Hidden Cost of Chasing Clinical Trial Follow-up" Poster presented at the 8th Nottingham International Breast Cancer Conference by Norman Williams, Jenny Chan, and Joan Houghton.
• December 2003 "Delays in Ethics Committee Approval - an English Perspective" Poster presented at the 26th Annual San Antonio Breast Cancer Symposium by Norman Williams, Kathryn McRae, and Joan Houghton.

Publications (2003 to present)

• Baum M., Buzdar A. The current status of aromatase inhibitors in the management of breast cancer. Surgical Clinics of North America. 2003;83:973-994.
• Thornton H., Edwards EA., Baum M. Women need better information about routine mammography. Br Med J. 2003; 327:101-103.
• UK Coordinating Committee on Cancer Research (UKCCCR) Ductal Carcinoma In Situ (DCIS) Working Party* on behalf of the DCIS trialists in the UK, Australia and New Zealand. Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial. Lancet 2003;362:95-102. PubMed

Publications (before 2003)

• The ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists’ Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002;359:2131-2139. PubMed
• Baum, M. A new strategy for cancer. Prospect 2002:44-49.
• Baum, M. The philosphical surgeon: 1 The philosophy of science and evidence-based medicine. Surgery 2001 [jan]:i-ii.
• Fellowes D., Fallowfield LJ., Saunders CM., Houghton J. Tolerability of hormone therapies for breast cancer: how informative are documented symptom profiles in medical notes for ‘well-tolerated’ treatments? Breast Cancer Res Treat 2001;66(1)73-81.
• Early Breast Cancer Trialist’ Collaborative Group. Favourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomised trials. Lancet 2000;355(9217):1757-1770.
• Kiebert G., Wait, S., Bernhard J., Bezak A., Cella D., Day R., Houghton J., Moinpour C., Scott C., Stephens R. Practice and policy of measuring quality of life and health economics in cancer clinical trials: A survey among co-operative trial groups. Quality of Life Research 2000;9:1073-1080.
• Mittra I., Baum M., Thornton H., Houghton J. Is clinical breast examination an acceptable alternative to mammographic screening? Br Med J 2000;321(7268)1071-1073.
• Warnakulasuriya S., Jia C., Johnson J., Houghton J. P53 and P-glycoprotein expression are significant prognostic markers in advanced head and neck cancer treated with chemo/radiotherapy. Journal of Pathology 2000;191:33-38.
• Baum M., Houghton J. Contribution of randomised controlled trials to understanding and management of early breast cancer. British Medical Journal 1999;319:568-571.
• Menon KV., Hodge A., Houghton J., Bates T. Body mass index, height and cumulative menstrual cycles at the time of diagnosis are not risk factors for poor outcome in breast cancer. The Breast 1999;8:1-6.

Books, Book Chapters and Editorials

• Baum M. Background. In: History and Advancement of Anastrozole in the Treatment of Breast Cancer. A Buzdar, M Baum. (Editors). Pubs: The Royal Society of Medicine Press Ltd. 2003;1:3-6.
• Houghton J., Cuzick J., Baum M. Anastrozole in the early breast cancer setting – the ATAC trial: Design and statistical considerations. In: History and Advancement of Anastrozole in the Treatment of Breast Cancer. A Buzdar, M Baum. (Editors). Pubs: The Royal Society of Medicine Press Ltd. 2003;6:37-44.
• Williams N. ATAC continuation: An overview. In: History and Advancement of Anastrozole in the Treatment of Breast Cancer. A. Buzdar, M. Baum. (Editors). Pubs: The Royal Society of Medicine Press Ltd. 2003;15:91-97.
• Houghton J., George WD. Radiotherapy and tamoxifen after complete excision of Ductal Carcinoma In Situ of the Breast. In: Ductal Carcinoma In Situ of the Breast. MJ Silverstein, A Recht and MD Lagios (Editors). Pubs: Lippincott Williamson + Wilkins. 2002;44:453-455.
• Tobias JS., Houghton J., Henderson IC. (Editors). Breast Cancer: New Horizons in Research and Treatment. Pubs: Arnold (Publishers) Ltd. 2001.
• Tobias JS., Houghton J. Could cytotoxic chemotherapy have a future in the chemoprevention of breast cancer. In: Breast Cancer: New Horizons in Research and Treatment. Tobias JS, Houghton J, Henderson IC. (Editors). Arnold (Publishers) Ltd. 2001;13:157-163.
• Houghton J, Tobias JS. Adjuvant radiotherapy in the management of early breast cancer. In: Tobias JS, Houghton J, (Editors). Breast Cancer: New Horizons in Research and Treatment. Arnold (Publishers) Ltd. 2001;16:188-194.
• Tobias JS, Houghton J, Riley DL. 'Moving the goalposts' - a review of clinical trial strategies in early breast cancer. In: Breast Cancer: New Horizons in Research and Treatment. JS Tobias, J Houghton. and IC Henderson. (Editors). Arnold (Publishers) Ltd. 2001;17:195-203.
• Williams NR, Houghton J, Baum M. Conventional Adjuvant Hormonal Therapy In: Textbook of Breast Cancer: A Clinical Guide to Therapy 2nd Edition, G Bonadonna, GN Hortobagyi and AM Gianni. (Editors). Martin Dunitz Publishers. 2001;10:151-160.

Abstracts

• Williams NR, Chan, J, Houghton J. Hidden cost of chasing clinical trial follow-up. The Breast 2003 (in Press)
• Baum M. The ATAC (Arimidex, Tamoxifen, Alone or in Combination) adjuvant breast cancer trial in postmenopausal (PM) women. Breast Cancer Research and Treatment. 2002;69[3]:210.
• Vaidya JS., Joseph D., Hilaris B., Tobias JS., Houghton J., D’Souza D., Sainsbury R., Keshtgar M. Taylor I., Baum M. Targeted intraoperative radiotherapy (TARGIT) for breast cancer: an international trial. Breast Cancer Research and Treatment. 2002;76(Suppl.1)452.
• Bates T., Fennessy M., Latteier J., MacRae K., Riley DL., Houghton J., Baum M. Surgery for early breast cancer improves survival in the elderly: Result of a randomized trial of tamoxifen alone versus surgery plus tamoxifen. Br J Surg. 2001;88:41.
• Bates T., Fennessy M., Riley DL., Baum M., Houghton J., MacRae K. Breast cancer in the elderly: Surgery improves survival. The results of a Cancer Research Campaign Trial. Eur J Cancer 2001;37(Suppl 5):7.
• Baum M., Houghton J., Odling-Smee W., et al. Adjuvant Zoladex in premenopausal patients with early breast cancer; results from the ZIPP trial. The Breast 2001;10:(Suppl 1)P64, S32-S33.
• Baum M., Houghton J., Sawyer, W., et al. Management of premenopausal women with early breast cancer: Is there a role for Goserelin? Proceedings of the American Society of Clinical Oncology 2001;20 103:27a.
• Cuzick J. George WD., Houghton J. UKCCCR Trial of tamoxifen and/or radiotherapy for DCIS. Br J Can 2001;85:(Suppl 1):2.
• Houghton J., Fellowes D., Fallowfield L., Saunders C. Patient’s view of minimum acceptable benefits from adjuvant hormonal therapy. The Breast 2001;10:(Suppl 1)P86, S38.
• Houghton J, Fellows D, Fallowfield L, Saunders C. Measuring outcomes from adjuvant hormone therapy: the patients’ view of the minimum acceptable benefit from treatment. Eur J Can 2001;37:S54-S55.
• Houghton J, Potyka I, Tobias J, Baum M, Odling-Smee W. Prophylactic radiotherapy following surgery for early breast cancer – Is the benefit mainly to patients with involved margins? Results from a Cancer Research Campaign Trial. Proceedings of the American Society of Clinical Oncology 2001;20 122:31a.
• Lovett B., Sawyer W., Houghton J., Taylor I. Systematic review of randomized controlled trials comparing surgical techniques in the general surgical subspecialities. Br J Surg 2001;88:34-34.
• Potyka I., Houghton J., Baum M., Odling-Smee W. Is there a need for local prophylactic irradiation of good prognosis women with early breast cancer who are receiving systemic adjuvant therapy? Results from the CRC trial at 10 years. The Breast 2001;10:(Suppl 1)P39, S25.
• Potyka I., Houghton J., Baum M., Odling-Smee, W. Duration of tamoxifen therapy in the management of early operable breast cancer for postmenopausal patients – results from the CRC trial after completion of trial therapy. The Breast 2001;10:(Suppl 1)P50, S29.
• Tobias J.S., Monson K.M., Glaholm J., MacDougall R.H., Gupta N.K., Peto, J., Sawyer, W., Houghton, J. Early results from the UK Head and Neck (UKHAN) Trial: The role of chemotherapy in primary management of advanced head and neck cancer. Br J Can 2001;85(Suppl 1):29.
• Tobias J., Monson K., Gupta N., MacDougall H., Glaholm J., Peto J., Sawyer, W., Houghton, J. Does chemotherapy have a role in the management of patients with advanced head and neck cancer? Early results from the UK Head and Neck (UKHAN) Trial. Proceedings of the American Society of Clinical Oncology 2001;20:888,223a.
• Tobias J., Monson K., Gupta N., MacDougall H., Glaholm J., Peto., R. Sawyer W., Houghton, J. UKHAN 1: A prospective multi-centre randomised trial investigating chemotherapy as part of initial management in advanced head and neck cancer. International Congress of Radiation Oncology Melbourne, Australia. February 2001
• Vaidya JS., Baum M., Tobias JS., Houghton J., et al. Targeted Intra-operative radiotherapy (TARGIT) for breast cancer – a randomised trial. Eur J Cancer 2001:37(Suppl 5):37.
• Baum M. The ATAC (Arimidex, Tamoxifen, Alone or in Combination) adjuvant breast cancer trial in post-menopausal women: baseline patient and tumour characteristics. European Journal of Cancer 2000;36:S69.
• Dowsett M, on behalf of the ATAC Trialists' Group. Pharmacokinetics of 'Arimidex' and tamoxifen alone and in combination in the ATAC adjuvant breast cancer trial. Breast Cancer Research and Treatment 2000;64:64.
• Forbes J, on behalf of the ATAC Trialists' Group. The ATAC (Arimidex, Tamoxifen, Alone or in Combination) breast cancer adjuvant trial in post-menopausal women: a model for adjuvant trials. Journal of Steroid Biochemistry and Molecular Biology 2000.
• Howell A, on behalf of the ATAC Trialists' Group. The ATAC ('Arimidex', Tamoxifen, Alone or in Combination) adjuvant breast cancer trial in post-menopausal women: regional variation in knowledge of hormone receptor status prior to randomisation into the trial. Annals of Oncology 2000;11.
• Jackson TL, Duffy SRG, on behalf of the ATAC Trialists' Group (Endometrial Sub-Protocol). The ATAC ('Arimidex', Tamoxifen, Alone or in Combination) Trial: transvaginal ultrasound scan findings overestimate observed pathological findings in postmenopausal gynaecologically asymptomatic women before treatment. Breast Cancer Research and Treatment 2000;64:64.
• Jackson TL, Duffy SRG, on behalf of the ATAC Trialists' Group (Endometrial Sub-Protocol). The ATAC ('Arimidex', Tamoxifen, Alone or in Combination) Trial: The effectivenessof transvaginal ultrasonography and diagnostic hysteroscopy in the prediction of endometrial abnormalities in asymptomatic postmenopausal women. Breast Cancer Research and Treatment 2000;64:63.
• Jackson TL, Duffy SRG, on behalf of the ATAC Trialists Group. The ATAC (Arimidex, Tamoxifen, Alone or in Combination) adjuvant breast cancer trial in post-menopausal women: baseline endometrial sub-protocol data. European Journal of Cancer 2000;36:S69.
• Sainsbury JRC, on behalf of the ATAC Trialists' Group. The ATAC ('Arimidex', Tamoxifen, Alone or in Combination) adjuvant breast cancer trial in post-menopausal women: regional variations in surgical practice in patients recruited into the trial. Annals of Oncology 2000;11.
• Dowsett M, Houghton J, Baum M, et al. ER, PgR, c-erbB2 and EGFr in patients randomised to adjuvant tamoxifen or no treatment: associations with treatment benefit. The Breast 1999;8(4):241.
• Fellowes D, Saunders C, Fallowfield LJ, Houghton J. Do patients regard hormone therapy received in early breast cancer as worthwhile? Psycho-oncology 1999;8(6)(Suppl):50.
• Houghton J, Mustacchi G, Fosser V, et al. Local progression of disease in elderly patients with breast cancer managed in trials of tamoxifen vs surgery plus tamoxifen: combined data from the 'GRETA' and 'CRC' trials. Programme / Proceedings of ASCO 1999;18:576A.
• Pinder SE, Cuzick J, Houghton J, George D, Ellis JO, (on behalf of the UKCCCR DCIS Trial Working Group). The Breast 1999;8(4):242.
• Potyka I, Houghton J, Baum M, Odling-Smee W. CRC Breast Cancer Trials Group. Is postoperative radiotherapy necessary in the management of early breast cancer patients who also receive adjuvant systemic treatment. The Breast 1999;8(4):215.
• Thrush S, Christie R, Brooks M, Bates A, Houghton J, Coltart RS, Bates, T. Is radiotherapy to the breast and lower axilla adequate treatment for a positive node sample. The Breast 1999;8(4):235-235.
• Baum M, Houghton J, (on behalf of the Chart Steering Committee). Arimidex, tamoxifen alone or in combination (ATAC) adjuvant trial in post-menopausal breast cancer. European Journal of Cancer 1998;34:S39.
• Fellowes D, Fallowfield LJ, Saunders CM, Houghton J. Patient evaluation of hormone therapy in breast cancer: Quantifying trade-offs between survival gains and quality of life. European Journal of Cancer 1999;34(5)(suppl):122.